Home > Insider Trading > Filing (0001493152-22-034965)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1394319	Tracon Pharmaceuticals Inc.	TCON	Biological Products, (No Disgnostic Substances) (2836)	342037594

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1595855	Opaleye Management Inc.	One Boston Place, 26Th Floor Boston MA 02108		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.01 Per Share	Acquisiton	2022-12-06	221,539	$0.01	4,011,539	No	4	X	Indirect	By Opaleye, L.P.
Common Stock, Par Value $0.01 Per Share	Disposition	2022-12-06	1,539	$1.44	4,010,000	No	4	S	Indirect	By Opaleye, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	X	Indirect	By Opaleye, L.P.
No	4	S	Indirect	By Opaleye, L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Prefunded Warrants	Disposition	2022-12-06	221,539	$0.01	221,539	$0.01

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,667,974	2020-08-27	2030-08-27	No	4	X	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, Par Value $0.01 Per Share	4,125,000	Indirect	By Managed Account

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Prefunded Warrants	$0.01	2020-08-31	2030-08-31	1,358,593	1,358,593	Indirect
Common Stock	Prefunded Warrants	$0.01	2022-06-21	2032-06-21	2,205,018	2,205,018	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2030-08-31	1,358,593	1,358,593	Indirect
2032-06-21	2,205,018	2,205,018	Indirect

Footnotes

On December 6, 2022, the Reporting Person exercised prefunded warrants to purchase 221,539 shares of the Issuer's common stock for $0.01 a share. The Reporting Person paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 1,539 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 220,000 shares.
This disposition of shares by the Reporting Persons was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the purchase by the Reporting Persons of 1,539 shares purchased on June 21, 2022 at a price of $1.3127 per share. The Reporting Persons have already sent the Issuer a check in the amount of $195.92, representing the full amount of the Reporting Person's pecuniary interest in the disgorgeable profit arising from such transactions.
Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
The warrants may not be exercised to the extent that such exercise would cause the reporting person and its affiliates to beneficially own more than 19.99% of the Issuer's then outstanding common stock.